Cognition and Quality of Life Among Survivors of Pediatric Non-CNS Cancers Receiving Ototoxic Therapy

Abstract

Date Presented 04/13/21 Children with cancer treated with platinum-based chemotherapy are at risk for developing hearing impairment (HI), one of several late effects associated with treatment. HI is associated with decreased socioemotional development, academic performance, and quality of life (QOL) among survivors of central nervous system (CNS) tumors. This is the first study to examine the impact of ototoxic HI on cognition and QOL among a cohort of survivors of pediatric non-CNS cancers. Primary Author and Speaker: Taniya Easow Varughese Contributing Authors: Julia Ferringer, Emily Grambo, Hannah Murkens, Jillian Smith, and Emily Scifo